Developmental and Epileptic Encephalopathy Market Analysis: Promising Pharma Growth Outlook through 2034 - DelveInsight

DelveInsight's report titled "Developmental and Epileptic Encephalopathy Market Insights, Epidemiology, and Market Forecast - 2034" delivers a comprehensive analysis of the disease, including historical and projected epidemiology, along with key market trends across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To gain deeper insights into market outlook, drug adoption, treatment landscape, and epidemiological trends, visit: https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Developmental and Epileptic Encephalopathy Market Report
• The Developmental and Epileptic Encephalopathy market across the 7MM was valued at approximately USD 2.1 billion in 2023 and is expected to experience substantial growth, registering a strong CAGR during the forecast period.
• In March 2026, Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of September 27, 2026.
• In July 2025, Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application and granted Fast Track designation for ABS-1230, an expected first-in-class, orally administered small molecule KCNT1 inhibitor, for the treatment of KCNT1-related epilepsy. KCNT1-related epilepsy is a rare, severe and often fatal pediatric developmental epileptic encephalopathy with a U.S. prevalence of approximately 2,500 individuals. Additionally, ABS-1230 received conditional approval from the Human Research Ethics Committee (HREC) in Australia for human clinical evaluation.
• In May 2025, researchers from Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital participated in a multicenter clinical trial led by Capsida Biotherapeutics to evaluate a novel therapy targeting STXBP1-related DEE, a severe pediatric epilepsy disorder. Additionally, the U.S. FDA cleared the Investigational New Drug (IND) application for CAP-002, a first-in-class intravenously delivered gene therapy developed for this condition.
• In May 2025, Capsida Biotherapeutics also confirmed FDA clearance of the IND for CAP-002, its innovative intravenous gene therapy for STXBP1-DEE. This therapy leverages a proprietary capsid engineered to cross the blood-brain barrier while minimizing off-target effects and is manufactured in a GMP-certified facility.
• The U.S. market for Developmental and Epileptic Encephalopathies was estimated at nearly USD 1.65 billion in 2023 and is projected to grow with the introduction of emerging therapies and expanded indications for existing treatments.
• Within EU4 and the UK, Germany accounted for the largest market share, contributing approximately 35% in 2023.
• Japan's Developmental and Epileptic Encephalopathies drug market was valued at around USD 80 million in 2023.
• In 2023, anti-epileptic drugs dominated the treatment market with approximately USD 900 million across the 7MM, followed by EPIDIOLEX/EPIDYOLEX.
• In October 2024, Capsida Biotherapeutics received Orphan Drug Designation (ODD) from the U.S. FDA for CAP-002, its leading investigational gene therapy targeting DEE associated with STXBP1 mutations.
• The total prevalence of Developmental and Epileptic Encephalopathies across the 7MM was approximately 284,000 cases in 2023 and is expected to increase during the forecast period.
• Lennox-Gastaut syndrome (LGS) and Tuberous sclerosis complex (TSC)-associated epilepsy represent the largest contributors to the DEE patient population. In the United States alone, there were nearly 50,000 LGS cases and approximately 47,100 TSC-associated epilepsy cases in 2023.
• The total patient population in EU4 and the UK was estimated at around 104,000 cases in 2023.
• Among EU4 and the UK, Germany reported the highest number of DEE cases, accounting for nearly 34% in 2023.
• Japan recorded approximately 34,000 DEE cases in 2023.
• Key companies operating in the DEE market include Takeda/Ovid Therapeutics, Epygenix, Longboard Pharmaceuticals, Stoke Therapeutics, Neurocrine Biosciences, Praxis Precision Medicines, Zogenix, Inc., Xenon Pharmaceuticals, and others.
• Leading therapies in development or use include Soticlestat (OV935/TAK935), EPX-100, EPX-200, EPX-300, LP352, STK-001, NBI-921352, PRAX-562, Fenfluramine, XEN496, and others.
• Epidemiological analysis indicates that Developmental and Epileptic Encephalopathy is more prevalent in males compared to females.
• The DEE market is expected to grow significantly due to rising disease prevalence and increased awareness. Furthermore, the launch of multiple pipeline therapies at different stages is anticipated to transform market dynamics.

Developmental and Epileptic Encephalopathy Overview
Developmental and Epileptic Encephalopathy (DEE) comprises a group of severe epilepsy disorders characterized by frequent, drug-resistant seizures. These conditions are often associated with encephalopathy, leading to significant developmental delays or regression in cognitive and functional abilities.

Get a free sample report: https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Developmental and Epileptic Encephalopathy Epidemiology Insights
The epidemiology section presents detailed insights into historical, current, and projected trends across the seven major markets (7MM) from 2020 to 2034. It analyzes key drivers of these trends using multiple studies and expert opinions while providing a comprehensive breakdown of diagnosed patient populations and future projections.

Developmental and Epileptic Encephalopathy Epidemiology Segmentation
The Developmental and Epileptic Encephalopathy market report includes epidemiological segmentation for the period 2020-2034 across the 7MM, covering:
• Total prevalence of Developmental and Epileptic Encephalopathy
• Severity-specific Developmental and Epileptic Encephalopathy prevalence
• Gender-based Developmental and Epileptic Encephalopathy prevalence
• Diagnosed cases of episodic and chronic Developmental and Epileptic Encephalopathy

Download the report to explore factors influencing epidemiological trends: https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Developmental and Epileptic Encephalopathy Drug Uptake and Pipeline Development
Zorevunersen (STK-001): Stoke Therapeutics
Zorevunersen is an investigational new medicine for the treatment of Dravet syndrome. It is a proprietary antisense oligonucleotide (ASO) and has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. The drug is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrences of seizures and significant non-seizure comorbidities. This RNA-based approach is not gene therapy but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA). STK-001 has been granted orphan drug designation by the FDA and the EMA and rare pediatric disease designation by the FDA as a potential new treatment for Dravet syndrome. Stoke Therapeutics's discussions with global regulatory agencies are underway. The company is on track to provide a regulatory update on Phase III registrational plans for zorevunersen in the second half of 2024.

Bexicaserin (LP352): Longboard Pharmaceuticals
Bexicaserin is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of seizures associated with DEEs such as Dravet syndrome, LGS, tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other epileptic disorders. LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures. LP352 is the only 5-HT2c receptor superagonist being dose-optimized for the refractory epilepsy population. Longboard plans to advance bexicaserin (LP352) into a global Phase III program. The company also reported positive topline data from a Phase Ib/IIa clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12-65 years old with DEEs, including LGS, Dravet syndrome, and other DEEs.

Key Developmental and Epileptic Encephalopathy Therapies and Companies
• Soticlestat (OV935/TAK935): Takeda/Ovid Therapeutics
• EPX-100, EPX-200, EPX-300: Epygenix
• LP352: Longboard Pharmaceuticals
• STK-001: Stoke Therapeutics
• NBI-921352: Neurocrine Biosciences
• PRAX-562: Praxis Precision Medicines
• Fenfluramine: Zogenix, Inc.
• XEN496: Xenon Pharmaceuticals

Explore more about emerging therapies shaping the Developmental and Epileptic Encephalopathy market: https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Developmental and Epileptic Encephalopathy Market Drivers
• The recent approval of Ztalmy, the first therapy for CDKL5 Deficiency Disorder in the United States, is contributing to market expansion. Continued R&D efforts are expected to address the unmet need for licensed treatments.
• Strong adoption of therapies such as Epidiolex and Fintepla is further driving market growth by expanding their prescriber base.

Developmental and Epileptic Encephalopathy Market Opportunities
• The current DEE treatment landscape remains limited, offering significant opportunities for pharmaceutical companies to establish a strong presence in this relatively untapped market.
• Emerging therapies with improved seizure management have the potential to enhance treatment outcomes and improve patient quality of life.

Developmental and Epileptic Encephalopathy Market Report Scope
• Study Period: 2020-2034
• Coverage: 7MM (United States, EU5, and Japan)
• Key Companies: Takeda/Ovid Therapeutics, Epygenix, Longboard Pharmaceuticals, Stoke Therapeutics, Neurocrine Biosciences, Praxis Precision Medicines, Zogenix, Inc., Xenon Pharmaceuticals, and others
• Key Therapies: Soticlestat, EPX-100/200/300, LP352, STK-001, NBI-921352, PRAX-562, Fenfluramine, XEN496, and more
• Therapeutic Scope: Marketed and emerging therapies
• Market Dynamics: Key drivers and barriers
• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, and entry strategies
• Additional Insights: Unmet needs, KOL perspectives, analyst views, and reimbursement landscape

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.